Internal Medicine News - Sibutramine metaanalysis
Sibutramine use was significantly associated with weight loss and appears to improve glycemic control and lipid profile in type 2 diabetics, reported Roberto Vettor, M.D., of the University of Padova, Italy, and his colleagues.
In a metaanalysis of eight placebo-controlled, double-blind trials, 552 obese patients with type 2 diabetes were randomized to sibutramine treatment, and 541 were randomized to placebo. Body weight decreased by a mean of 5.5 kg in sibutramine users and by 0.9 kg in placebo users. Waist circumference decreased a mean of 5.3 cm in treated patients and by 1.1 cm with placebo (Diabetes Care 2005;28:942-9).
Related Results
Sibutramine in the management of obesityEffectiveness of sibutramine - Letter to the EditorSibutramine in the real worldSibutramine maintains weight lossPetition questions safety of sibutramine
Mean changes in basal blood glucose were small, but the difference between the two groups was statistically significant, the investigators said. Treatment benefits also were seen in the levels of glycated hemoglobin (Hb[A.sub.1c]), serum triglycerides, and HDL cholesterol.
COPYRIGHT 2005 International Medical News Group
COPYRIGHT 2008 Gale, Cengage Learning
